Electrokinetic Fluids Modulate Membrane Potential for Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory neurodegenerative diseases such as multiple sclerosis, Alzheimer's, and Parkinson's are inadequate, with existing therapies only marginally limiting disease progression and causing significant side effects, and there is a need for more effective anti-inflammatory strategies.
Innovation Solution
Administration of electrokinetically-generated fluids enriched with oxygen, which modulate cellular membrane potential and conductivity, reducing inflammation by altering the activity of membrane-associated proteins and intracellular signal transduction pathways, potentially used in combination with other anti-inflammatory agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-inflammatory therapies are administered, then inflammation is reduced, but significant side effects occur and disease progression is only marginally limited
Solution Approach 1:
The patent changes the chemical parameters of the treatment by using electrokinetically-generated fluids with unique properties (oxygen-containing nanostructures, altered pH, reactive oxygen species) compared to conventional anti-inflammatory drugs. This parameter change enables effective inflammation reduction while minimizing harmful side effects through a different mechanism of action that modulates cellular membrane potential and conductivity rather than broadly suppressing immune function
Solution Approach 2:
The electrokinetically-generated fluid acts as an intermediary substance that transfers energy and chemical signals to modulate cellular function. The fluid contains oxygen-containing nanostructures and reactive species that interact with cell membranes as intermediaries to alter membrane potential and conductivity, thereby reducing inflammation through a targeted intermediary mechanism rather than direct drug-receptor interaction that causes side effects
2Reliability
If existing therapies are used to treat inflammatory neurodegenerative diseases, then some disease progression is limited, but the overall effectiveness is inadequate
Solution Approach 1:
The patent applies preliminary action by modulating cellular membrane potential and conductivity before inflammatory damage fully progresses. The electrokinetically-generated fluid pre-conditiones cells by altering their electrical properties, making them more resistant to inflammatory injury and preventing downstream pathological cascades, thereby improving overall treatment effectiveness
Solution Approach 2:
The invention changes fundamental cellular parameters (membrane potential, membrane conductivity) rather than merely addressing inflammatory symptoms. This parameter change approach targets the underlying electrophysiological dysfunction in neurodegenerative diseases, leading to more effective disease progression limitation compared to conventional therapies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The electrokinetically-generated oxygen-enriched fluids effectively reduce inflammatory cytokines and promote a localized decrease in inflammatory mediators, offering a more targeted and potentially more effective treatment for inflammatory neurodegenerative diseases with reduced side effects.
Implementation Method 1
electrokinetically-generated fluids enriched with oxygen, which modulate cellular membrane potential and conductivity
Implementation Method 2
charge-stabilized oxygen-containing nanostructures
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.